Reading Time: 6 minutes
Introduction
A quiet crisis is unfolding across UK hospitals. It is not driven by a lack of scientific knowledge or therapeutic options, but by outdated, fragmented, and predominantly manual diagnostic workflows. Nowhere is this more evident than in the pathway from blood sample to specialist interpretation in haematology.
Multiple national reviews have identified pathology and diagnostics as a major operational bottleneck within the NHS, with delays, duplication, and poor interoperability between systems contributing to excess cost and avoidable harm (NHS England, 2017; Royal College of Pathologists, 2019). Although the NHS does not publish a single consolidated figure for inefficiency in blood film reporting specifically, modelling based on excess length of stay, duplicated testing, delayed treatment, and workforce inefficiency suggests the total system cost plausibly approaches £200 million per year.
This is not merely a financial problem. It is a patient safety problem, a workforce productivity problem, and a structural weakness in one of the NHS’s most critical diagnostic pathways.
The Vital Role of Blood Films
Blood films, also known as peripheral blood smears, remain a cornerstone of diagnostic haematology. When automated Full Blood Count (FBC) analysers detect abnormal results, microscopic examination of a stained blood film allows direct assessment of cell morphology, including abnormalities in red cells, white cells, and platelets that cannot be fully characterised by automation alone (Bain, 2020).
Blood film review plays a decisive role in diagnosing conditions such as acute leukaemias, haemolytic anaemias, bone marrow failure syndromes, and thrombotic microangiopathies. One of the most critical of these is Thrombotic Thrombocytopenic Purpura (TTP), a rare but life-threatening condition characterised by thrombocytopenia, microangiopathic haemolytic anaemia, and organ dysfunction (Scully et al., 2017). Untreated, mortality can exceed 90 percent, while even with modern therapy it remains a medical emergency requiring rapid diagnosis and treatment (Joly et al., 2017).
In such conditions, blood film interpretation is not optional or confirmatory. It is often the trigger for life-saving intervention. Delays of hours or days materially change outcomes.
The Paper Chase: A System Stuck in the Past
Despite the clinical importance of blood films, the supporting referral infrastructure in many NHS trusts remains fundamentally analogue. In a typical workflow, a biomedical scientist identifies an abnormal result, completes a paper or semi-manual referral form, prints laboratory results, and dispatches the physical glass slide to a remote haematologist, often at another site or within a regional network.
This process introduces multiple sources of delay and risk:
- Manual transcription and duplication of data
- Printing, scanning, and re-entry of the same information into multiple systems
- Physical transport delays for slides
- Repeated phone and email queries to clarify missing information
- Fragmentation between laboratory information systems, electronic patient records, and specialist reporting platforms
National pathology reviews have repeatedly highlighted these inefficiencies and called for end-to-end digital pathways (NHS England, 2017; Royal College of Pathologists, 2019). Yet, in practice, blood film referral workflows in many organisations still rely on processes that would be recognisable decades ago.
For time-critical conditions such as TTP or acute leukaemia, these delays are not just operational inconveniences. They directly translate into avoidable clinical risk.
The True Cost: More Than Money
The economic impact of inefficient blood film reporting is driven by several interacting factors.
First, delayed specialist input prolongs hospital stays. A single excess inpatient day typically costs several hundred pounds, and delays of two to three days are common when diagnostic pathways stall. Across thousands of patients annually, this alone represents tens of millions of pounds of avoidable expenditure.
Second, diagnostic uncertainty drives additional testing. Clinicians compensate for lack of definitive interpretation by ordering repeat blood tests, imaging, or invasive procedures such as bone marrow biopsies. These not only increase cost but also expose patients to unnecessary procedures and anxiety.
Third, workforce inefficiency is substantial. Highly trained haematologists and senior laboratory staff spend disproportionate time coordinating logistics, retrieving slides, and managing administrative complexity rather than performing clinical interpretation and decision making (Royal College of Pathologists, 2019).
Finally, delayed diagnosis leads to more advanced disease at presentation, more intensive treatment, and poorer outcomes, particularly in haematological malignancies and severe anaemias. Later treatment is almost always more expensive and less effective than early intervention.
Taken together, these factors explain how a seemingly narrow process inefficiency can plausibly generate system-level costs approaching hundreds of millions of pounds annually.
The Specialist Shortage Crisis
These process failures are magnified by chronic workforce shortages in consultant haematology and pathology more broadly. The NHS has repeatedly acknowledged that diagnostic services face significant staffing constraints, particularly outside major teaching centres (Royal College of Pathologists, 2019; NHS England, 2020).
District general hospitals often lack on-site haematology specialists, relying instead on regional networks. In theory, digital connectivity should make such networks highly efficient. In practice, analogue referral mechanisms mean that cases can take days to reach the right expert, even when clinical urgency is high.
The result is a system in which geographical location continues to influence access to timely specialist diagnosis, despite the technological means to eliminate that inequality.
A Digital Prescription for Change
Digital pathology and telehaematology offer a clear and evidence-based route out of this bottleneck.
Whole slide imaging now allows blood films to be scanned at high resolution and shared instantly with remote specialists. Structured electronic referral forms ensure that complete clinical context accompanies each case. Integrated platforms allow real-time collaboration, triage, and audit.
Empirical studies show that digital microscopy significantly reduces turnaround times for peripheral blood smear review while maintaining diagnostic quality (Katz et al., 2022). Broader telepathology and digital pathology programmes have consistently demonstrated improvements in access to expertise, reporting speed, and system resilience (NHS England, 2017; Williams et al., 2018).
The NHS has already committed to digital pathology as part of its diagnostic modernisation strategy. Extending this approach systematically to blood film workflows is a logical and overdue step.
The Human Impact: Stories Behind the Statistics
Behind every delayed report is a patient whose treatment was postponed, a clinician forced to manage uncertainty, and a family left waiting for answers.
Patients with aggressive leukaemias whose diagnosis is delayed by days often require more intensive chemotherapy and have poorer prognoses. Individuals with rare haemolytic anaemias may experience repeated admissions and unnecessary investigations before a specialist review finally identifies the underlying cause.
While these stories are rarely visible in aggregated performance data, they represent the real human cost of diagnostic inefficiency.
Towards a More Efficient Future
The NHS Long Term Plan and diagnostic transformation programmes emphasise speed, integration, and networked expertise (NHS England, 2019). Blood film reporting is an ideal candidate for this model.
A fully digital, integrated pathway would:
- Reduce excess length of stay
- Eliminate unnecessary repeat testing
- Improve productivity of scarce specialist staff
- Improve outcomes through faster diagnosis
- Reduce regional inequalities in access to expertise
The pandemic demonstrated that rapid digital transformation is possible when there is sufficient strategic will. Applying the same urgency to diagnostic pathways would yield lasting benefits.
Conclusion: An Investment in Better Care
The estimated £200 million annual cost of inefficient blood film reporting is not an inevitable feature of modern healthcare. It is the consequence of outdated systems and fragmented processes.
Replacing paper-based workflows with integrated digital pathways is not merely an IT upgrade. It is a patient safety intervention, a workforce productivity intervention, and a financially responsible reform.
Ensuring that every abnormal blood film reaches the right expert at the right time should be a basic standard of care in a modern health system.
Conflict of Interest Disclosure:
Optymum SS is currently developing HemoVisionAI, a digital haematology diagnostics solution. The views expressed in this article are informed by the company’s experience working with UK pathology services and by internal modelling and indicative estimates, supplemented by analysis of publicly available evidence. They should be read with the understanding that Optymum SS has a commercial interest in the development of digital solutions within this space.
References
Bain, B.J. (2020). Blood Cells: A Practical Guide. 6th ed. Oxford: Wiley-Blackwell.
Joly, B.S., Coppo, P. and Veyradier, A. (2017). Thrombotic thrombocytopenic purpura. Blood, 129(21), pp.2836–2846.
Katz, B., et al. (2022). Remote digital microscopy improves hematology laboratory workflow by reducing peripheral blood smear analysis turnaround time. Applied Clinical Informatics, 13(1), pp.122–130.
NHS England (2017). Digital First: Clinical Transformation through Pathology Innovation. London: NHS England.
NHS England (2019). The NHS Long Term Plan. London: NHS England.
NHS England (2020). Diagnostics: Recovery and Renewal. London: NHS England.
Royal College of Pathologists (2019). Meeting Pathology Demand: Histopathology Workforce Census and Analysis. London: RCPath.
Scully, M., et al. (2017). International Society on Thrombosis and Haemostasis guidelines for the diagnosis and management of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 15(2), pp.312–322.
Williams, B.J., et al. (2018). Digital pathology: a systematic review of diagnostic accuracy and clinical impact. Journal of Clinical Pathology, 71(9), pp.769–776.
About The Author: Optymum SS is a networked, international organisation of UK chartered scientists. UK chartered scientists represent the best professional scientists working in the UK and abroad. We utilise our innovative business model to support the provision of the best, most cost-effective solutions to challenges within the broad life sciences –advancing well-being and quality of life. For more information about working with us or joining our partnership, please get in touch.
